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Abstract 
The potential for human exposure to the brominated flame retardant, 
hexabromocyclododecane (HBCD) has given rise to health concerns, yet there is relatively 
limited knowledge about its possible toxic effects and the underlying molecular mechanisms 
that may mediate any impacts on health. In this study, unbiased transcriptomic and 
metabolomic approaches were employed to investigate the potential molecular changes that 
could lead to toxicity of HBCD under concentrations relevant to human exposure conditions 
using in vitro models. A concentration-dependent cytotoxic effect of HBCD to A549 and 
HepG2/C3A cells was observed based on MTT assays or CCK-8 assays with EC50 values of 
27.4 μM and 63.0 μM, respectively. Microarray-based transcriptomics and mass 
spectrometry-based metabolomics revealed few molecular changes in A549 cells or 
HepG2/C3A cells following a 24-hour exposure to several sub-lethal concentrations (2 to 
4000 nM) of HBCD. Quantification of the level of HBCD in the HepG2/C3A exposed cells 
suggested that the flame retardant was present at concentrations several orders of magnitude 
higher than those reported to occur in human tissues. We conclude that at the concentrations 
known to be achievable following exposure in humans HBCD exhibits no detectable acute 
toxicity in A549 cells, representative of the lung, or in HepG2/C3A cells, hepatocytes 
showing some xenobiotic metabolic capacity. 
Key Words: HBCD; A549 cells; HepG2/C3A cells; microarray; DIMS; cytotoxicity.  
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1. Introduction 
Hexabromocyclododecane (HBCD) is a widely used brominated flame retardant (Covaci et al 
2006; Marvin et al 2011). HBCD is persistent, bioaccumulative and is capable of long-range 
atmospheric transport (Marvin et al 2011) and has been detected in various environmental 
media including indoor air and dust (Roosens et al 2009). Human exposure to HBCD has 
been confirmed by its presence in breast milk, adipose tissue and blood (Marvin et al 2011; 
Rawn et al 2014). HBCD levels detected in breast milk samples in Spain were up to 188 ng/g 
lipid( median 27 ng/g lipid) (Eljarrat et al 2009). A recent study (Rawn et al 2014) reported 
concentrations of HBCD in fetal liver (median 29 ng/g lipid) and placental tissues (median 49 
ng/g lipid) collected between 1998 and 2010 in Canada. HBCD has also been detected in 
human serum at up to 856 ng/g lipid (Thomsen et al 2007). These studies confirm that human 
exposure to HBCD is widespread.  
Potentially adverse effects of HBCD have been reported in animal models and human cell 
lines (Marvin et al 2011). Disruption of thyroid function has been found in rats (van der Ven 
et al 2006; Ema et al 2008;), fish (Palace et al 2008; Palace et al 2010) and chicken (Crump et 
al 2008) following exposure to HBCD. Low micromolar concentrations of HBCD have been 
shown to give rise to neurotoxic effects in in vitro cultured neuronal cells (e.g. PC12 cells 
(Dingemans et al 2009) and SH-SY5Y cells (Al-Mousa and Michelangeli 2012)) by 
interfering with calcium (Ca
2+
) homeostasis and intracellular signalling pathways. 
Hepatotoxicity of HBCD has been reported in a wide range of studies, which showed that 
liver is a major  main target organ (Marvin et al 2011; Hakk et al 2012). Long term exposure 
to HBCD at a relatively high dose (30 mg/kg/day, 28 days) increased liver weight in female 
rats (van der Ven et al 2006) and induced hepatic cytochrome P450 (CYP) enzyme activities 
(CYP2B1 and CYP3A1) in rats (Germer et al 2006; Cantón et al 2008). In juvenile rainbow 
trout (Ronisz et al 2004) and Chinese rare minnow (Zhang et al 2008), HBCD inhibited 
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activities of cytochrome P450s (CYPs) in the liver after 28-day exposure. The mRNA 
expression of CYPs (CYP2H1 and CYP3A37) were up-regulated in chicken (Gallus gallus) 
hepatocytes exposed  to ≥ 1μM HBCD for 24 and 36 hours (Crump et al 2008). 
In several in vitro studies, induction of cell apoptosis by exposure to high concentrations of 
HBCD in HepG2 cells (Hu et al 2009; An et al 2014) and human L02 hepatocytes (An et al 
2013) has been suggested to result from increased production of reactive oxygen species 
(ROS). However, a slight increase in ROS has also been observed after low concentration 
(10
−7−10−1 μM) exposures in human L02 hepatocytes, while there was no acute toxic effect 
reported (An et al 2013; Zou et al 2013). More studies are necessary to better understand 
whether any molecular changes result from concentrations that are realistic for human 
exposure.  
Since human exposure to HBCD can occur via inhalation as mentioned above, the lung 
represents one of the target organs. Therefore, in the present study an adenocarcinomic 
human alveolar basal epithelial cell line (A549 cells) was selected as an in vitro model to test 
the potential effects of HBCD. This cell line has been widely used in toxicology studies and 
shows similar metabolic properties to normal human alveolar type 2 epithelial cells in terms 
of xenobiotic interactions (Hukkanen et al 2000; Vulimiri et al 2009). Hepatocytes are the 
major site of xenobiotic metabolism and hence represent an  important cellular target of 
xenobiotics (Deferme et al 2013).The HepG2/C3A cell line (a clonal derivative cell line of 
HepG2 cells that has been shown to exhibit a degree of xenobiotic metabolic capacity (Gerets 
et al 2012)) was employed here as a convenient alternative to primary human hepatocytes.  
Toxicogenomics is a valuable and increasingly used platform for investigating the molecular 
changes induced by toxicants. However, there are only a few ‘omics’ studies of the potential 
toxicity of HBCD. One example showed that the hypothyroidism reported in rats following a 
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28-day high dose exposure (30 and 100 mg HBCD/kg/day) of HBCD (Germer et al 2006) 
was found to correlate well with gene expression changes in the cholesterol biosynthesis 
pathway in rat liver, as revealed by transcriptomic analysis (Cantón et al 2008). A proteomic 
study of zebrafish (Danio rerio) liver cells found that protein metabolism decreased after 72-
hour exposure to 5 µM HBCD (Kling and Förlin 2009). Metabolomics has been applied to a 
wide range of toxicological studies, including in mechanistic toxicology (Nicholson et al 
2002) and ecotoxicology (Bundy et al 2009) but no metabolomics study of the effects of 
HBCD has yet been reported.  
The aim of this study was to apply unbiased ‘omics’ approaches to investigate the potential 
molecular toxicity of HBCD to humans under as realistic experimental conditions as possible 
with in vitro cell line models, i.e. including serum within the cell culture media. A wide range 
of sub-lethal exposure concentrations of a commercial mixture of HBCD was investigated 
including levels comparable to those reported previously in human serum. Specifically, 
oligonucleotide microarray based transcriptomics and direct infusion mass spectrometry 
(DIMS) based metabolomics were applied to determine gene expression and metabolic 
profiles of A549 and HepG2/C3A cells exposed to HBCD, respectively. Used in 
combination, these ‘omics’ approaches can inform on both upstream regulatory processes as 
well as downstream functional molecular responses, providing insights into potential adverse 
effects of HBCD. 
 
2. Materials and Methods  
2.1 Chemicals and reagents 
All chemicals, including 1,2,5,6,9,10-hexabromocyclododecane (CAS Number: 3194-55-6, 
purity >95%) were obtained from Sigma-Aldrich (Dorset, UK) unless otherwise stated. 
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2.2 Cell culture 
A549 cells were originally bought from European Collection of Cell Cultures (ECACC) and 
subcultures were kept under liquid nitrogen. A549 cells were cultured in DMEM medium 
(catalogue no.: D6429, Sigma-Aldrich, Dorset, UK) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) (PAA, Cölbe, Germany), 100 U penicillin/mL and 100 μg 
streptomycin/mL (PAA, Cölbe, Germany), 2 µM L-glutamine (PAA, Cölbe, Germany) and 
incubated in 37°C with humidified air containing 5% CO2. HepG2/C3A cells were 
generously provided by Prof. R. Blust from the University of Antwerp, Belgium. 
HepG2/C3A cells were cultured in Williams’ E medium (catalogue no.:W4128, Sigma-
Aldrich, Dorset, UK) supplemented with 5% heat-inactivated fetal bovine serum (FBS) 
(PAA, Cölbe, Germany), 100 U penicillin/mL and 100 μg streptomycin/mL (PAA, Cölbe, 
Germany), 4 µM L-glutamine (PAA, Cölbe, Germany) and 0.4 µM sodium pyruvate (Sigma-
Aldrich, Dorset, UK) and incubated in 37°C with humidified air containing 5% CO2. Cells 
were digested with 0.25% trypsin-EDTA and sub-cultured at 80% to 90% confluence. 
Exponentially growing cells were used for all assays.  
2.3 Cytotoxicity assays  
The cytotoxicity of HBCD to A549 cells was assessed by the MTT assay. A549 cells were 
seeded in 96-well plates (5 × 10
3
 cells per well) and incubated at 37°C with a humidified 
atmosphere containing 5% CO2 for 24 hours. Then, cells were treated with HBCD at various 
concentrations (0.1, 1, 5, 10, 25, 50 and 100 μM; with six replicates at each concentration) for 
24 hours. The percentage of viable A549 cells was calculated. Concentration-response curves 
were plotted and the half maximal effective concentration (EC50) values were then calculated 
using sigmoidal dose-response curve equation. The cytotoxicity of HBCD to HepG2/C3A 
cells was also evaluated by the CCK-8 assay using a commercial kit, according to the 
manufacturers’ instructions (Dojindo Laboratories, Kumamoto, Japan). Briefly, HepG2/C3A 
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cells (2× 10
4
 cells per well) were cultured in a 96-well plate overnight and the cells were 
treated in six replicates with several concentrations (0.1, 1, 5, 10, 25, 50 and 75 μM) of 
HBCD in culture medium for 24 hours. The viability of cells in the CCK-8 assays, in terms of 
EC50 values, was calculated using the same approach as that used for the MTT assay. (Further 
details are available in Supplementary Material.)  
2.4 HBCD- exposure experiments and sample preparation for metabolomics and 
transcriptomics 
2.4.1 A549 cells  
A549 cells were exposed to several HBCD concentrations: 2 nM (in the media, termed Very 
low dose group), 20 nM (termed Low dose group), 200 nM (termed Medium dose group) and 
2 µM (termed High dose group). In the control group, a concentration of 0.5% DMSO (v/v) 
was applied (used as a vehicle). Each dose group included six or eight replicates. After 24-
hour exposure, cells were rapidly washed in PBS and then quenched in 60% methanol / 40% 
water (pre-cooled on dry ice). Cells were carefully scraped into the methanol/water solution 
and transferred into Eppendorf tubes for metabolite and RNA extraction. Further details of 
the cell harvesting can be found in Supplementary Material. To extract the metabolites, 
further solvents were added to the cell pellets (in 400µL methanol/water solution) to a final 
solvent ratio of methanol/chloroform/water of 1:1:0.9 (v/v/v). After vortexing and 
centrifuging, the mixture separated into two phases (upper polar phase and lower non-polar 
phase). For each sample, a 300 µL aliquot of the polar phase was transferred into a 1.5mL 
Eppendorf tube and dried in a speed vac concentrator (Thermo Savant, Holbrook, NY) for 4 
hours, then frozen at -80°C until analysis. The non-polar aliquots were not used in this study. 
Further details of the extraction procedure can be found in Supplementary Material.  
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Total RNA of quenched cells was isolated using Qiagen’s mini RNeasy Kit and QIAshredder 
(Qiagen, Crawley, UK) according to the manufacturer’s protocol. RNA was quantified with a 
NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA), and the integrity of 
RNA was verified with a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).  
2.4.2 HepG2/C3A cells  
Similar methodologies were used to culture, expose and harvest HepG2/C3A cells as above, 
with some subtle modifications to maximise the recovery of RNA and metabolites. 
Specifically, the HepG2/C3A cells were exposed to 4 µM HBCD or 10 µM 7,12-
dimethylbenz[a]anthracene (DMBA) for 24 hours; 0.5% DMSO was used as a vehicle in all 
groups. Each treatment group consisted of six replicates. Following the exposures, the cells 
were harvested and the metabolites and RNA were extracted in a similar manner to that 
described above. The procedure is detailed in the Supplementary Material.  
2.5 Metabolomics analyses 
2.5.1 Direct infusion mass spectrometry (DIMS) analysis and data processing 
The dried polar extracts of cells were re-suspended in 150 μL 80:20 (v/v) methanol:water 
(HPLC grade) with 20 mM ammonium acetate, vortexed and centrifuged at 14000 rpm, 4°C 
for 10 min. Each sample was loaded into three wells of a 96-well plate (10 µL per well) and 
then analysed (in triplicate) using direct infusion Fourier transform ion cyclotron resonance 
mass spectrometry in negative ion mode (LTQ FT Ultra, Thermo Fisher Scientific, Germany, 
coupled to a Triversa nanoelectrospray ion source, Advion Biosciences, Ithaca, NY, USA). 
Mass spectra were recorded utilising the selected ion monitoring (SIM) stitching approach 
from m/z 70 to 590 (Southam et al 2007) and then processed using custom-written Matlab 
scripts as previously reported (Southam et al 2007;  Kirwan et al 2014). In brief, time domain 
(‘transient’) data were collected, Fourier transformed and internally mass calibrated. Only 
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mass spectral peaks with a signal-to-noise ratio above 3.5 were retained. Mass spectra of the 
three technical replicates for each sample were filtered into a single peak list (with only those 
peaks present in ≥ 2 of the 3 spectra retained). Each filtered peak list (one per sample) was 
then further filtered to retain only those peaks that were present in 80% of all biological 
samples in the entire dataset, and missing values were imputed using the k-nearest neighbours 
(KNN) algorithm. The resulting matrices of peak intensity data (termed “DIMS dataset”) 
were normalised by the probabilistic quotient (PQN) method prior to statistical analyses. 
2.5.2 Statistical analyses of metabolomics data 
For univariate statistical analysis, one way ANOVA (or t-test) with Benjamini-Hochberg 
correction was conducted on the peaks in the normalised DIMS datasets to determine whether 
they changed intensity significantly between control and HBCD or DMBA treatment groups 
(at a false discovery rate (FDR) < 10% to correct for multiple hypothesis testing). For 
multivariate statistical analysis, the normalized DIMS datasets were generalized log 
transformed and principal component analysis (PCA) performed using PLS_Toolbox 
(Eigenvector Research, Wenatchee, USA) in MatLab (version 7, the Math-Works, Natick, 
USA). ANOVA (or t-test) with a Tukey-Kramer’s post-hoc test was conducted on the PC 
scores for the top few principal components from each model (with an FDR of <10%) to 
evaluate the statistical significance of the treatments on the basis of the overall metabolic 
profiles.  
2.6 Transcriptomic analysis  
For RNA samples from A549 cells, six replicates (randomly selected from the total of eight 
replicates) were used for each of the HBCD treated groups (2 nM (Very low), 20 nM (Low), 
200 nM (Medium) and 2 µM (High)) while the solvent (DMSO) control group comprised of 
eight replicates. For RNA samples from HepG2/C3A cells, a total of 16 samples were 
subjected to microarray analyses, comprising six samples from the HBCD (4 µM) treated 
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group, six from the solvent (DMSO) control group, and the remaining four from the DMBA 
(10 µM) positive control group.  
The procedures for microarray analysis were performed following the manufacturer's 
protocols (Agilent Technologies, Santa Clara, CA). (Further details are available in 
Supplementary Material.) Microarray data processing and analyses were performed within 
GeneSpring version GX7.3.1 and GX11 (Agilent Technologies, Santa Clara, CA) and 
MultiExperimental Viewer v4.9 (Saeed et al 2003). The normalised microarray dataset was 
log2 transformed and then subjected to Significance Analysis of Microarrays (SAM) (Tusher 
et al 2001) embedded in MultiExperimental Viewer v4.9 to identify significant differential 
gene expression between groups. The delta parameter was adjusted to achieve an FDR <5% 
and this delta value was applied to select significantly-regulated genes. Any significantly 
altered genes were then analysed using the Functional Annotation Clustering (FAC) tool 
contained in the Database for Annotation, Visualisation and Integrated Discovery (DAVID) 
(Huang et al 2009) to determine the most relevant pathways and processes based on the Gene 
Ontology annotation function, with FDR <5% selected for the significant functions. Gene set 
enrichment analysis (Subramanian et al 2005) was also applied to the above normalised 
microarray dataset to determine differentially expressed gene sets in HBCD or DMBA treated 
groups comparing to control. Microarray datasets are available in the ArrayExpress database 
under accession numbers：E-MTAB-2173 and E-MTAB-2174.  
Quantitative real time-PCR (qPCR) analysis was performed to quantify the mRNA levels of a 
selected set of six genes in A549 or HepG2/C3A cells treated with HBCD or DMBA. (Details 
are available in Supplementary Material.) 
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2.7 Quantification of HBCD in A549 and HepG2/C3A cells and cell media  
To measure the cellular uptake of HBCD after exposure, A549 and HepG2/C3A cells were 
exposed to 2 μM and 4 μM HBCD, respectively, in both FBS-containing and FBS-free 
media. Following 24-hour exposures, HBCD levels were quantified in both the cell pellets 
and media using the LC-MS/MS method(Van den Eede et al 2012). Briefly, 10 ng of each of 
13
C-labelled α- and β-HBCDs and 25 ng 13C-labelled γ-HBCD (supplied in 10 µL methanol) 
were added as internal (surrogate) standards while the samples were extracted from weighed 
cell pellets and cell media using liquid-liquid extraction with 3 mL of 
hexane:dichloromethane (DCM) (3:2) mixture in clean, stoppered, 10 mL centrifuge tubes. 
The clean extract was evaporated under a gentle stream of nitrogen and re-dissolved in 150 
µL of methanol containing 50 pg/µL of d18-labelled α-HBCD used as a recovery 
determination (syringe) standard for QA/QC. Separation of the target analytes was achieved 
using a dual pump Shimadzu LC-20AB Prominence LC equipped with a SIL-20A 
autosampler, a DGU-20A3 vacuum degasser and an Agilent Pursuit XRS3 C18 reversed phase 
analytical column (150 mm × 2 mm i.d., 3 µm particle size). (Details of procedures can be 
found in Supplementary Material)  
The concentrations of HBCD diastereomers in the samples were calculated according to the 
response factors of the respective 
13
C-labelled internal standard for each diastereomer. The 
recovery ratios were calculated from the total amount of α-, β- and γ-HBCDs (ΣHBCDs) in 
the cell pellets after exposure, divided by the nominal amount that was added into the 
exposure media. Average concentrations of ΣHBCDs detected in the cell media were also 
calculated where each treatment group included three biological replicates. 
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3. Results  
3.1 Cytotoxicity of HBCD to A549 cells and HepG2/C3A cells 
Concentration-dependent cytotoxicity of HBCD to A549 cells and HepG2/C3A cells after 24-
hour treatments were observed (Fig. 1). At relatively low concentration ranges from 0 to 10 
μM, HBCD exhibited minimal cytotoxicity with the viability of HepG2/C3A cells remaining 
greater than 90%, while for the A549 cells the viability remained greater than 80%. HBCD 
was more toxic to A549 cells than to HepG2/C3A cells with EC50 values of 27.4 μM and 63.0 
μM, respectively, in the presence of serum in the exposure media.  
 
Fig. 1. Cytotoxic effects of HBCD to A549 cells and HepG2/C3A cells. Cell viability of 
A549 cells (triangle shape) and HepG2/C3A cells (round shape) was examined using the 
MTT assay and CCK-8 assay, respectively, after exposure of the cells to different 
concentrations (0-100 μM for A549 cells; 0-75 μM for HepG2/C3A cells) of HBCD for 24 
hours. Results are expressed as the percentage (mean ± standard deviation, n=6) of cell 
viability compared to controls treated with the appropriate vehicle (DMSO). 
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In order to explore potential molecular events in cells at sub-toxic concentrations, 2 μM was 
selected as the highest concentration for exposure of A549 cells to HBCD, which was 
approximately 8% of EC50 (27.4 μM).. Three additional treatment groups were included, each 
10-fold lower in concentration. The experimental design therefore consisted of exposing 
A549 cells to HBCD at 2 nM, 20 nM, 200 nM and 2 μM, with the appropriate vehicle 
(DMSO) as a control group, so as to maximise the relevance of our findings to likely human 
exposure levels. Following a similar strategy for the HepG2/C3A cells, 4 μM was used as the 
exposure concentration for the ‘omics’ studies (which was also corresponded to 
approximately 8% of EC50, 63.0 μM). DMBA at 10 μM was employed as a reference 
treatment (positive control) for the gene expression study in HepG2/C3A cells. Although the 
5 μM HBCD exposure appeared to increase the HepG2/C3A cell viability (Figure 1), two 
further cytotoxicity assays were conducted at this concentration that showed that this increase 
was not significant compared to controls (data not shown). 
3.2 Molecular responses of A549 cells exposed to HBCD 
3.2.1 Gene expression profiles of A549 cells exposed to HBCD 
Oligonucleotide microarrays were employed to evaluate gene expression profiles of A549 
cells after 24-hour exposures to four concentrations of HBCD, as detailed above. There was 
no clear separation of gene expression profiles between different treatment groups in A549 
cells in PCA scores plot (Fig. 2A). The ANOVAs of the top four PC scores combined with a 
Tukey-Kramer's post hoc test (Table 1) also showed that there were no significant differences 
in the gene expression profiles between control and HBCD treated groups in A549 cells. 
Significance analysis of microarrays (SAM) found no significantly altered individual genes 
compared to controls, which is consistent with the results from the PCA of the gene 
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expression dataset. Gene Set Enrichment Analyses also indicated there were no significantly 
enriched gene sets involving KEGG pathways in HBCD treated groups (data not shown). 
 
Fig. 2. PCA scores plots of microarray dataset (A) and DIMS dataset (B) in A549 cells 
exposed to HBCD for 24 hours. Legend: controls (blue), Very low dose (2 nM) group (dark 
green), Low dose (20 nM) group (green), Medium dose (200nM) group (pink) and High dose 
(2 μM) group (red). Biological replication comprised n=6 (microarray) and n=8 (DIMS) in 
HBCD treatment groups; n=8 in the control group. 
 
Quantitative RT-PCR analysis of six genes of interest (CYP1A1 and CYP3A4: related to 
xenobiotic metabolism, CDK2: cell division/growth, EEF1A1: protein biosynthesis, GSR: 
oxidative stress response, and GJB1: cell communication) revealed that only expression of 
CYP3A4 in A549 cells treated with 20 nM (Low dose) and 200 nM (Medium dose) HBCD 
was slightly down-regulated (Fig. 3A), while no significant changes were observed in the 
microarray analysis after exposure to the different concentrations of HBCD for 24 hours. The 
expression levels of the other five genes were not significantly altered, in agreement with the 
results of the microarray analysis. 
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Fig. 3. qPCR analysis of mRNA expression of six selected genes in A549 cells (A) and 
HepG2/C3A cells (B) following HBCD or DMBA treatments for 24 hours. Data were 
obtained from quadruplicate PCR reactions of four biological replicates. Differences to the 
solvent control were tested by one-way ANOVA or Student’s t-test (*P <0.05). Results are 
presented as mean ± standard deviation. 
 
3.2.2 Metabolic responses of A549 cells exposed to HBCD 
Polar metabolites extracted from HBCD-exposed A549 cells were analysed by direct infusion 
mass spectrometry based metabolomics. After spectral processing, the DIMS dataset 
comprised of a total of 1457 mass spectral peaks that were subjected to PCA to visualize the 
similarities and differences of the metabolic profiles between control and HBCD-treated 
groups. The PCA scores plot (Fig. 2B) showed no separation in the metabolic profiles 
measured from HBCD-treated and control groups for PC1 vs. PC2, an observation that was 
supported by ANOVA of the top four PC scores data and subsequent analysis using Tukey-
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Kramer's post hoc tests. These results (Table 1) indicate no separation along PC1, PC2 and 
PC4, though HBCD-treated and control samples separated along the PC3 axis (representing 
4.8% of variance in DIMS dataset) (p =0.005). However, univariate statistical analyses of all 
1457 peaks revealed that none changed significantly in response to HBCD across all four 
concentration groups (FDR < 10%). 
3.3 Molecular responses of HepG2/C3A cells exposed to HBCD 
3.3.1 Gene expression profiles of HepG2/C3A cells exposed to HBCD 
Since no significant molecular changes had been discovered in A549 cells after exposure to 
the subtoxic HBCD concentration, HepG2/C3A cells, representing a system with a higher 
xenobiotic metabolic activity, were exposed to 4 μM HBCD (less than 10% of EC50) and 10 
μM DMBA (as a positive control to induce gene expression). DMBA is a polycyclic aromatic 
hydrocarbon with carcinogenic properties and a CYP1A1 -substrate. The PCA scores plot 
indicated no separation of the gene expression profiles between HBCD treated group and the 
control group, whereas the analyses distinguished marked differences between DMBA group 
and the other groups (Fig. 4A). The statistical significance of the top four PC scores was 
verified by a t-test; no significant differences between the HBCD and control group existed, 
but the DMBA and control samples were significantly different along PC1 (representing 
53.1% of the variance in the dataset, p=8.62x10
-6
). In addition, SAM of individual genes 
showed that there was no significant modulation of gene expression in the HBCD-treated 
group compared to the control group, while more than 300 probe sets changed in the DMBA 
treated group in HepG2/C3A cells (Table S1).  
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Fig. 4. PCA scores plots of microarray dataset (A) and DIMS dataset (B) in HepG2/C3A 
cells exposed to 4 μM HBCD and 10 μM DMBA for 24 hours. Legend: controls (blue), 4 
μM HBCD group (red) and 10 μM DMBA group (pink). Biological replication comprised 
n=6 (microarray) and n=6 (DIMS) in the control group and HBCD treatment groups; n=4 in 
10 μM DMBA group (as positive control in microarray analysis). 
 
The functional annotation tool (DAVID) was employed to determine the most relevant 
pathway(s) or process(es) involved in these significantly dysregulated genes in the DMBA-
treated group identified by SAM. The results (Table S2) suggest that p53 signalling and 
apoptosis are the most significantly altered pathways in DMBA-treated HepG2/C3A cells. 
GSEA showed similar results (Table S3) that cytokine-cytokine receptor interaction, p53 
signalling pathway, apoptosis and metabolism of xenobiotics by CYPs are the top enriched 
gene sets in the DMBA group, while no significant enrichment of gene sets was observed in 
the HBCD-treated groups. In HepG2/C3A cells, the mRNA expression of six selected genes 
was analysed by quantitative RT- PCR. This revealed similar trends as measured by 
microarray; including a remarkable up-regulation of CYP1A1(175-fold, p<0.0001) and slight 
down-regulation of GJB1 (0.7-fold, p<0.0001) in the DMBA group, while there was no 
significantly altered expression of genes in cells treated with 4 μM HBCD, except a slightly 
increased expression of EEF1A1 (1.4-fold, p=0.004) (Fig. 3B).  
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3.3.2 Metabolomics analysis of HepG2/C3A cells exposed to HBCD  
Metabolic profiles of HepG2/C3A cells exposed to 4 μM HBCD were measured by DIMS. A 
total of 2128 mass spectral peaks were subjected to PCA and univariate analysis. No distinct 
separation was observed in the PCA scores plot (Fig. 4B) of which the top four PC scores 
were evaluated by t-test, confirming no significant differences (Table 1). Further t-tests on 
each of the 2128 individual peaks in the HBCD exposed group compared to the control group 
confirmed that there was no significant metabolic change in HepG2/C3A cells exposed to 4 
μM HBCD for 24 hours. However, after extended HBCD exposure to72 hours, subtle 
metabolic changes were found in DIMS dataset. 85 (of total 3412) MS peaks significantly 
changed (Table S4) which is likely to be the results of extension of exposure time or the 
delayed effects of 24 hours exposure. 
3.4 Uptake of HBCD into A549 and HepG2/C3A cells  
The recovery of HBCD from cell pellets and the concentrations of HBCD in the cell media 
were evaluated, with the objective to facilitate comparisons between the concentrations of 
HBCD in the present study and those reported in human tissue and biofluids.  
The results (Fig. 5) showed that when cultured in FBS-containing media, an average of 
12.4% of the nominal amount of HBCD added to the exposure system was detected in A549 
cell pellets, while in those cell pellets collected from the FBS-free media, approximately 
double the amount (20.9%) was measured in the cells. In HepG2/C3A cells, recoveries of 
HBCD from cell pellets exposed in FBS-containing or FBS free media were considerably 
higher, and 50.7% and 48.1% respectively. This suggested that the capacity for HepG2/C3A 
cells to uptake HBCD was higher than for A549 cells. As shown in Table 2, the average 
concentrations of HBCD in A549 cell pellets were 15.9 and 27.5 ng mg
-1
 (wet weight) from 
FBS-containing exposure media and FBS-free media, respectively. However, the average 
concentrations of HBCD in HepG2/C3A cells from FBS-containing media and FBS-free 
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media were 96.2 and 99.0 ng mg
-1
 (wet weight) respectively, which were much higher than in 
A549 cells.  
 
Fig. 5. Recovery of HBCD from cell pellets in A549 cells and HepG2/C3A cells exposed 
to HBCD for 24 hours. A549 cells and HepG2/C3A cells were treated with 2 μM and 4 μM 
HBCD, respectively, in both serum (FBS)-containing media and serum-free media (without 
FBS). Recoveries are expressed as the percentage of detectable amount of HBCD from cell 
pellets after exposure, relative to the total nominal amount of HBCD added to the exposure 
media ± standard deviation (n=3). 
 
In addition to affecting uptake in A549 cells, the presence of FBS in the media also affected 
the post-exposure concentrations of HBCD in the cell media itself. In A549 cells, following 
the 24-hour exposures, the concentration of HBCD in 10% FBS-containing media was 1133.7 
ng/mL (Table 2), which is more than 20 times higher than HBCD measured in the FBS-free 
media. There was a similar difference in HepG2/C3A cell media (Table 2) where the 
concentration of HBCD in 5% FBS-containing media were considerably higher than in FBS-
free media (939.7 ng/mL versus 409.9 ng/mL, respectively).  
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4. Discussion 
The widespread use of HBCD has given rise to increasing health concerns following human 
exposure via various routes. Inhalation has been considered as one (albeit minor) pathway of 
human exposure to HBCD (Marvin et al 2011). There is therefore a particular interest in 
investigating effects in lung cells as this organ has relatively high exposure and in liver cells 
that play a critical role in the detoxification (or activation) of xenobiotic chemicals and in 
which protective compensatory changes are often seen. A549 lung epithelial cells and 
HepG2/C3A liver cells were thus selected as in vitro models to investigate the potential toxic 
effects of HBCD in this study.  
The EC50 value of cytotoxicity of HBCD to HepG2/C3A cells in this study (63.0 μM) was 
similar to the value observed in HepG2 cells exposed to HBCD (ca. 50 μM) (Hu et al 2009) ), 
with both studies conducted containing serum in the exposure media. Furthermore, in the 
immortalised human hepatocyte L02 cell line, the EC50 for a 24-hour exposure to HBCD was 
reported as ca. 60 μM (An et al 2013). Hence, the EC50 value for this hepatic cell line treated 
with HBCD is consistent with previously published values, for the case of exposures 
conducted in the presence of serum which more closely reflects the in vivo situation. 
However, in the absence of FBS in the exposure media, the EC50 values of HBCD were 
reported as being as low as ca. 3 μM in neuronal cell lines (Reistad et al 2006; Al-Mousa and 
Michelangeli 2012). The discrepancy between these reported EC50 values might be explained 
by differences in the cell type or different levels of serum in the exposure media. The higher 
serum protein levels could result in a reduction in the free concentration of xenobiotic such as 
phenanthrene, a hydrophobic polycyclic aromatic hydrocarbon (PAH), accompanied by an 
increase in the EC50 (Kramer et al 2012). Free concentrations of compounds are believed to 
be appropriate to characterise the toxic potency of a chemical in vitro which may be used for 
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in vivo extrapolation (Gülden et al 2013). In the present study, the concentrations of HBCD in 
cell pellets and cell media after exposure were quantified by LC-MS/MS. The lowest 
concentration of HBCD detected in A549 cell pellets after exposure was ca. 15 ng/mg cell 
pellet (wet weight) (Table 2), which is equal to 750,000 ng/g lipid (assuming 2% lipids in cell 
pellets which is similar to the lipid content in human liver (Rawn et al 2014)). This is several 
hundred times higher than the highest concentrations reported in human fetal liver (4,500 
ng/g lipid, median value: 29 ng/g lipid) and placental tissue (5,600 ng/g lipid, median value: 
49 ng/g lipid)(Rawn et al 2014). Thus, taking account of the EC50 values of HBCD in cells 
(63 μM in HepG2/C3A cells in this study), the concentrations achieved in cells that cause 
cytotoxicity are vastly higher than those reported in human tissues. In addition, mitochondrial 
reductive activity (MTT assay) and the integrity of the cell membrane (AK assay) in 
proliferating cells were disrupted by 60 μM HBCD to a greater extent than in confluent cells 
(Fig. S1 a and b). However, cell protein content was not significantly changed in the group 
exposed to 60 μM HBCD for 24 hours compared to the control group in either proliferating 
cells or confluent cells (Fig. S1 c). This suggests that 60 μM HBCD has no significant effects 
on cell proliferation of HepG2/C3A cells but that proliferating cells were more susceptible to 
HBCD toxicity.  
Molecular responses in terms of transcriptomic and metabolic levels were also assessed. 
Particular attention was given to cytochrome P450 monooxygenases (CYPs) that play critical 
roles in biotransformation activities and the induction of which is a common response to 
organic toxicants (Danielson 2002). Forty probe sets (representing 35 mRNAs of CYPs) were 
detected in the A549 microarray dataset (Table S5), whereas 43 probe sets (representing 33 
mRNAs of CYPs) were detected in the HepG2/C3A microarray dataset (Table S6). CYP1A1 
and CYP3A4 are both particularly important in phase I metabolism of aromatic 
hydrocarbons. The induction of CYP1A1 mRNA expression has been used as an indicator of 
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exposure to PAH (Castorena-Torres et al 2008). In the present study, HBCD did not induce 
mRNA expression for either of these CYP genes in A549 cells or HepG2/C3A cells after a 
24-hour exposure in contrast to the marked induction of CYP1A1 (175-fold) observed in 
response to DMBA treatment in HepG2/C3A cells.  
Several studies have reported that CYP3A4 is not expressed in A549 cells (Hukkanen et al 
2000; Courcot et al 2012). However, in a recent study, the expression of CYP3A4 was 
induced by 5 μM of the PAH benzo[a]pyrene (B[a]P) in A549 cells exposed for 14 hours, but 
not in HepG2 cells (Genies et al 2013). Fery et al. (2009) also reported that HBCD failed to 
induce CYP3A enzyme activity in HepG2 cells, but a significant induction was observed in 
primary cultured rat hepatocytes. In this study, mRNA expression of CYP3A4 was detected 
in both A549 and HepG2/C3A cells, and this was slightly down-regulated after a 24-hour 
exposure to 20 nM and 200 nM HBCD in A549 cells while there were no significant changes 
in HepG2/C3A cells. These observations show a noticeable contrast between HBCD and 
DMBA in the induction of CYP expression.  
The effects observed with DMBA are markedly different from those following HBCD 
exposure despite the latter showing intracellular accumulation. The extensive modification of 
the transcriptome as seen with DMBA includes evidence of a significant stress response at 
sub-toxic concentrations. These responses include the changes in CYP expression as 
mentioned above plus a range of other responses in the expression of genes involved in (e.g. 
apoptosis, regulation of cell proliferation, etc.). Neither two cell types showed this stress 
response to HBCD. This might be interpreted as a failure to react in a compensatory mode for 
protective purposes since no such response is seen right up to the concentrations that exhibit a 
toxic effect in the MTT assay or CCK-8 assay.  
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Few detectable transcriptomic and metabolomic responses after 24 hrs exposure might be due 
to missing the time window of some defensive or protective events. It has been reported that 
levels of CYP1A1 mRNA in A549 and HepG2 cells were modulated by B[a]P at an early 
stage of exposure (less than 4 or 6 hours) but not beyond (Genies et al 2013). Likewise, 
molecular responses after a relatively longer exposure may reflect chronic toxicity.  van der 
Ven et al.(2006)  reported that 28 days exposure to HBCD at a relatively high dose (30 
mg/kg/day) increased liver weight in female rats and induced hepatic CYP enzyme activities 
(CYP2B1 and CYP3A1) in rats (Germer et al 2006; Cantón et al 2008). However, a 72-hour 
exposure at relative low concentration (2 to 200 nM) did not significantly change the survival 
rate and the malformation rate in zebrafish embryos (Wu et al 2013). In the present study, 
additional DIMS analysis suggested possible metabolic changes (e.g. decrease of taurine) 
after 72hrs exposure in HepG2/C3A cells exposed to 4 μM HBCD, which might be 
responsive to stress after longer exposure or the delayed effects of 24 hours exposure.  
5. Conclusions 
‘Omics’ approaches were used to determine the potential molecular changes in two cell lines 
after exposure to HBCD over a wide range of concentrations in the presence of serum. Few 
molecular changes were observed in the ‘omics’ data despite employing cellular 
concentrations of HBCD up to several hundred times higher than those reported in human 
tissues and concentrations that approached cytotoxic levels. In contrast to the findings for the 
PAH, there was little evidence of a compensatory stress response to HBCD such as elevation 
of CYP or antioxidant systems. This lack of compensatory response does not equate to a lack 
of protection since cytotoxicity (mitochondrial dysfunction and loss of cell integrity) was 
only observed in HepG2/C3A cells exposed to a high concentration of HBCD (60 μM), at 
which the cellular concentrations achieved exceeded, by several orders of magnitude, the 
tissue concentrations observed in environmentally exposed organisms. 
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FIGURE LEGENDS 
Fig. 1. Cytotoxic effects of HBCD to A549 cells and HepG2/C3A cells. Cell viability of 
A549 cells (triangle shape) and HepG2/C3A cells (round shape) was examined using the 
MTT assay and CCK-8 assay, respectively, after exposure of the cells to different 
concentrations (0-100 μM for A549 cells; 0-75 μM for HepG2/C3A cells) of HBCD for 24 
hours. Results are expressed as the percentage (mean ± standard deviation, n=6) of cell 
viability compared to controls treated with the appropriate vehicle (DMSO). 
Fig. 2. PCA scores plots of microarray dataset (A) and DIMS dataset (B) in A549 cells 
exposed to HBCD for 24 hours. Legend: controls (blue), Very low dose (2 nM) group (dark 
green), Low dose (20 nM) group (green), Medium dose (200nM) group (pink) and High dose 
(2 μM) group (red). Biological replication comprised n=6 (microarray) and n=8 (DIMS) in 
HBCD treatment groups; n=8 in the control group. 
Fig. 3. qPCR analysis of mRNA expression of six selected genes in A549 cells (A) and 
HepG2/C3A cells (B) following HBCD or DMBA treatments for 24 hours. Data were 
obtained from quadruplicate PCR reactions of four biological replicates. Differences to the 
solvent control were tested by one-way ANOVA or Student’s t-test (*P <0.05). Results are 
presented as mean ± standard deviation. 
Fig. 4. PCA scores plots of microarray dataset (A) and DIMS dataset (B) in HepG2/C3A 
cells exposed to 4 μM HBCD and 10 μM DMBA for 24 hours. Legend: controls (blue), 4 
μM HBCD group (red) and 10 μM DMBA group (pink). Biological replication comprised 
n=6 (microarray) and n=6 (DIMS) in the control group and HBCD treatment groups; n=4 in 
10 μM DMBA group (as positive control in microarray analysis). 
Fig. 5.  Recovery of HBCD from cell pellets in A549 cells and HepG2/C3A cells exposed 
to HBCD for 24 hours. A549 cells and HepG2/C3A cells were treated with 2 μM and 4 μM 
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HBCD, respectively, in both serum (FBS)-containing media and serum-free media (without 
FBS). Recoveries are expressed as the percentage of detectable amount of HBCD from cell 
pellets after exposure, relative to the total nominal amount of HBCD added to the exposure 
media ± standard deviation (n=3). 
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Table 1. Summary of the principal component (PC) analyses of both microarray and 
DIMS datasets of A549 cells and HepG2/C3A cells following exposure to HBCD.  
 
Dataset   PC1 PC2 PC3 PC4 
A549_Microarray_24h 
variance 8.50% 7.34% 6.17% 5.66% 
p value 0.777 0.114 0.924 0.817 
A549_DIMS_24h 
variance 45.49% 20.01% 4.87% 4.11% 
p value 0.943 0.089 0.005 0.7 
HepG2/C3A_Microarray_24h 
variance 42.21% 12.75% 9.15% 6.36% 
p value 2.90E-07 0.502 0.272 0.962 
HepG2/C3A_DIMS_24h 
variance 37.51% 25.50% 9.95% 6.20% 
p value 0.251 0.14 0.78 0.873 
 (Groups in A549 cells: Control, Very Low dose, Low dose, Medium dose and High dose; groups in 
HepG2/C3A cells: Control, HBCD and DMBA). The variance explained (%) by PCs 1-4 are listed 
together with p values from ANOVAs (or t-tests) of these PC scores across all treatments 
(emboldened values indicate significance at a false discovery rate (FDR) <10%). 
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Table 2. Concentration of ΣHBCDs in cell pellets and cell media of A549 and 
HepG2/C3A cells after 24-hour exposure  
Cell types Types of 
Exposure 
Media 
Nominal 
concentration of 
ΣHBCDs in 
exposure media 
Average 
wet 
weight of 
cell 
pellets 
(mg) 
Concentration 
of HBCDs in 
cell pellets 
(ng/mg ) 
Concentration 
of HBCDs in 
cell media 
after 
exposure 
(ng/mL) 
A549 
No FBS 2 μM (1283 ng/mL) 19.8 ± 3.3 27.5 ± 5.0 46.9 ± 7.4 
10% FBS 2 μM (1283 ng/mL) 19.8 ± 4.0 15.9 ± 1.7 1133.7 ± 26.8 
HepG2/C3A 
No FBS 4 μM (2566 ng/mL) 25.4 ± 3.1 99.0 ± 26.0 409.9 ± 77.8 
5% FBS 4 μM (2566 ng/mL) 27.2 ± 2.8 96.2 ± 10.5 939.7 ± 124.3 
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Highlights 
1. Human cells lines were exposed to HBCD at sub-lethal concentrations for 24 hrs. 
2. Molecular response was studied by unbiased transcriptomic and metabolomic approaches. 
3. Few significant molecular changes were detected after 24 hrs exposure. 
4. The levels of HBCD in cells were quantified using LC-MS/MS method. 
